SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Bosutinib-d_8

Item No. 25460

Formal Name: 4-((2,4-dichloro-5-methoxyphenyl) amino)-6-methoxy-7-(3-(4-methyl piperazin-1-yl-2,2,3,3,5,5,6,6-d_8) propoxy)quinoline-3-carbonitrile
MF: $C_{26}H_{21}Cl_2D_8N_5O_3$
FW: 538.5
Chemical Purity: ≥98% (Bosutinib)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_8); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Bosutinib-d_8 is intended for use as an internal standard for the quantification of bosutinib (Item No. 12030) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Bosutinib-d_8 is supplied as a solid. A stock solution may be made by dissolving the bosutinib-d_8 in the solvent of choice, which should be purged with an inert gas. Bosutinib-d_8 is slightly soluble in organic solvents such as methanol and DMSO.

Description

Bosutinib is an inhibitor of c-Src and Abl kinases (IC_{50}s = 1.2 and 1 nM, respectively).[1,2] It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC_{50}s = 8.5, 22, 27, and 40 nM, respectively) among others.[3] Bosutinib inhibits Src-dependent cell proliferation (IC_{50} = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.[1] It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.[2]

References

1. Boschelli, D.H., Ye, F., Wang, Y.D., *et al.* Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. *J. Med. Chem.* **44(23)**, 3965-3977 (2001).
2. Golas, J.M., Arndt, K., Etienne, C., *et al.* SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. *CancerRes.* **63(2)**, 375-381 (2003).
3. Remsing Rix, L.L., Rix, U., Colinge, J., *et al.* Global target profile of the kinase inhbitor bosutinib in primary chronic myeloid leukemia cells. *Leukemia* **23(3)**, 477-485 (2009).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM